IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
Clinical trial NCT02614833 · COMPLETED
Trial details
- NCT number
- NCT02614833
- Sponsor
- Immutep S.A.S.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2020-03-01
- Enrollment
- 242
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.